Fed. Circ. Revives Astellas Patent Axed As Natural Law

By Ryan Davis · September 18, 2024, 9:29 PM EDT

The Federal Circuit on Wednesday vacated a lower court's invalidation of an Astellas Pharma overactive bladder medication patent for claiming only a natural law, saying the holding was improper because the...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Opinion

Case Information

Case Title

Astellas Pharma, Inc. v. Sandoz Inc.

Case Number

Court

Appellate - Federal Circuit

Nature of Suit

835 Patent - (ANDA) (Fed. Qst.)

Date Filed

June 16, 2023

Recent Articles By Ryan

September 26, 2024
Senate Patent Bill Markups Delayed Until After Election
August 20, 2024
Vax Patent Battles Heat Up As Attention On Pandemic Wanes
June 21, 2024
Drugmakers Decline To Drop Patent Listings After FTC Letters
April 04, 2024
Microsoft Unit Gets Fed. Circ. Alice Win On Imaging Patents
March 06, 2024
CBP Details Apple Watch Redesign OK In Masimo Patent Row
March 04, 2024
WTO Conference Ends Without COVID IP Waiver Expansion
January 17, 2024
Apple Drops Blood Oxygen Tech From New Watches After Ban
January 15, 2024
Apple Cleared To Avoid Import Ban With Redesigned Watch
December 28, 2023
Apple Watch Import Ban Put On Hold By Fed. Circ.
December 26, 2023
White House Won't Veto ITC Apple Watch Import Ban